Summary:
Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder characterized by insulin resistance and impaired glucose regulation. Despite the availability of various treatment options, achieving glycemic control remains a challenge for many patients. Two promising therapeutic agents, CagriSema and Tirzepatide, have shown potential in improving glycemic control and promoting weight loss in individuals with T2DM. This study aims to compare the efficacy of CagriSema and Tirzepatide in lowering blood sugar levels and reducing body weight in T2DM patients already on metformin therapy, with or without concurrent SGLT2 inhibitor use.
Criteria:- Age 18 years or above at the time of signing the informed consent.
- Diagnosed with type 2 diabetes ≥ 180 days before screening.
- Stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: Metformin with or without an SGLT2 inhibitor.
- HbA1c 7.0-10.5%
- BMI ≥ 30 kg/m2 at screening
Qualified Participants May Receive:
You will be paid for each completed study visit according to the details below with a possible total of $1,440.
You will also receive study medication at no cost to you